Zevra Therapeutics’ (ZVRA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a research report report published on Tuesday, Benzinga reports. HC Wainwright currently has a $15.00 price target on the stock. HC Wainwright also issued estimates for Zevra Therapeutics’ FY2026 earnings at $1.45 EPS and FY2027 earnings at $2.55 EPS.

Several other research analysts also recently issued reports on ZVRA. William Blair reaffirmed an outperform rating on shares of Zevra Therapeutics in a research note on Tuesday, March 12th. Cantor Fitzgerald reaffirmed an overweight rating on shares of Zevra Therapeutics in a research note on Monday, April 1st. Finally, Maxim Group lifted their price objective on Zevra Therapeutics from $12.00 to $18.00 and gave the stock a buy rating in a research report on Tuesday, April 2nd. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of Buy and a consensus price target of $19.50.

Zevra Therapeutics Price Performance

Zevra Therapeutics stock opened at $6.11 on Tuesday. The company has a market cap of $255.72 million, a P/E ratio of -4.53 and a beta of 1.97. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.10 and a current ratio of 2.10. Zevra Therapeutics has a one year low of $3.89 and a one year high of $7.28. The business has a fifty day moving average of $4.74 and a two-hundred day moving average of $5.41.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.09. The business had revenue of $3.43 million during the quarter, compared to the consensus estimate of $3.52 million. Zevra Therapeutics had a negative return on equity of 82.55% and a negative net margin of 181.76%. As a group, analysts predict that Zevra Therapeutics will post -1.54 earnings per share for the current fiscal year.

Institutional Trading of Zevra Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC increased its position in Zevra Therapeutics by 555.0% during the 4th quarter. International Assets Investment Management LLC now owns 6,550 shares of the company’s stock worth $43,000 after purchasing an additional 5,550 shares in the last quarter. VisionPoint Advisory Group LLC purchased a new stake in Zevra Therapeutics in the 3rd quarter valued at about $33,000. Tower Research Capital LLC TRC grew its holdings in Zevra Therapeutics by 134.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 9,673 shares of the company’s stock valued at $63,000 after buying an additional 5,545 shares during the period. Price T Rowe Associates Inc. MD purchased a new stake in Zevra Therapeutics in the 1st quarter valued at about $64,000. Finally, IFG Advisors LLC grew its holdings in Zevra Therapeutics by 45.0% in the 1st quarter. IFG Advisors LLC now owns 18,700 shares of the company’s stock valued at $108,000 after buying an additional 5,800 shares during the period. Hedge funds and other institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.